Presentation at the American Association of Cancer Research (AACR) Special Conference entitled "Addressing Critical Questions in Ovarian Cancer Research and Treatment" by Dr. Khursheed Anwer, Celsion's executive vice president and chief scientific officer, entitled "Immunological changes following intraperitoneal administration of a formulated IL-12 plasmid in combination with neoadjuvant chemotherapy in newly diagnosed advanced ovarian cancer patients."

Oct 2, 2017




Share This